{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:27:44Z","timestamp":1787146064369,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sleep Breath"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11325-026-03724-w","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:43:42Z","timestamp":1785977022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapy in obstructive sleep apnoea: a clinical guide"],"prefix":"10.1007","volume":"30","author":[{"given":"Shashank","family":"Shastry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Kimoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5418-5448","authenticated-orcid":false,"given":"Lancelot Mark","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"3724_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.smrv.2016.07.002","volume":"34","author":"CV Senaratna","year":"2017","unstructured":"Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, Hamilton GS, Dharmage SC (2017) Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev 34:70\u201381","journal-title":"Sleep Med Rev"},{"issue":"3","key":"3724_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.5664\/jcsm.27497","volume":"5","author":"LJ Epstein","year":"2009","unstructured":"Epstein LJ, Kristo D, Strollo PJ Jr et al (2009) Clinical guideline for the evaluation, management and long-term care of OSA in adults. J Clin Sleep Med 5(3):263\u2013276","journal-title":"J Clin Sleep Med"},{"issue":"1","key":"3724_CR3","first-page":"13","volume":"10","author":"SK Sharma","year":"2015","unstructured":"Sharma SK, Agrawal S, Damodaran D et al (2015) CPAP compliance in Indian patients with OSA: a multicenter study. Indian J Sleep Med 10(1):13\u201319","journal-title":"Indian J Sleep Med"},{"issue":"10","key":"3724_CR4","first-page":"1096","volume":"187","author":"A Wellman","year":"2013","unstructured":"Wellman A, Malhotra A, Jordan AS et al (2013) Pathogenesis of OSA and implications for pharmacologic treatment. Am J Respir Crit Care Med 187(10):1096\u20131103","journal-title":"Am J Respir Crit Care Med"},{"key":"3724_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.smrv.2016.12.003","volume":"37","author":"DJ Eckert","year":"2018","unstructured":"Eckert DJ (2018) Phenotypic approaches to OSA: new pathways for targeted therapy. Sleep Med Rev 37:45\u201359","journal-title":"Sleep Med Rev"},{"issue":"6","key":"3724_CR6","first-page":"2426","volume":"159","author":"NL Deacon","year":"2021","unstructured":"Deacon NL, Malhotra A (2021) Pharmacologic therapies for OSA: where are we now? Chest 159(6):2426\u20132433","journal-title":"Chest"},{"issue":"10","key":"3724_CR7","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1164\/rccm.201808-1493OC","volume":"199","author":"L Taranto-Montemurro","year":"2019","unstructured":"Taranto-Montemurro L, Messineo L, Sands SA, Azarbarzin A, Marques M, Edwards BA, Eckert DJ, White DP, Wellman A (2019) The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. A randomized, placebo-controlled, double-blind crossover trial. Am J Respir Crit Care Med 199(10):1267\u20131276. https:\/\/doi.org\/10.1164\/rccm.201808-1493OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3724_CR8","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.chest.2020.01.012","volume":"157","author":"L Taranto-Montemurro","year":"2020","unstructured":"Taranto-Montemurro L, Messineo L, Azarbarzin A, Vena D, Hess LB, Calianese NA, White DP, Wellman A, Sands SA (2020) Effects of the combination of atomoxetine and oxybutynin on OSA endotypic traits. Chest 157(6):1626\u20131636. https:\/\/doi.org\/10.1016\/j.chest.2020.01.012","journal-title":"Chest"},{"issue":"1","key":"3724_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/resp.14383","volume":"28","author":"M Kinouchi","year":"2023","unstructured":"Kinouchi M, Horie T, Sasai-Sakuma T, Inoue Y (2023) A randomized placebo-controlled crossover study of atomoxetine and oxybutynin combination therapy in Japanese patients with obstructive sleep apnea. Respirology 28(1):47\u201355. https:\/\/doi.org\/10.1111\/resp.14383","journal-title":"Respirology"},{"issue":"6","key":"3724_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.5664\/jcsm.10464","volume":"19","author":"B Corser","year":"2023","unstructured":"Corser B, Eves E, Warren-McCormick J (2023) Rucosky. Effects of atomoxetine plus a hypnotic on obstructive sleep apnoea severity in patients with a moderately collapsible airwa. J Clin Sleep Med 19(6):1035\u20131042","journal-title":"J Clin Sleep Med"},{"key":"3724_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.sleep.2023.11.006","volume":"113","author":"M Shahbazi","year":"2024","unstructured":"Shahbazi M, Heidari R, Tafakhori A, Samadi S, Nikeghbalian Z, Amirifard H, Najafi A (2024) The effects of atomoxetine and trazodone combination on obstructive sleep apnea and sleep microstructure: A double-blind randomized clinical trial study. Sleep Med 113:13\u201318 Epub 2023 Nov 7. PMID: 37979502","journal-title":"Sleep Med"},{"issue":"1","key":"3724_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5664\/jcsm.10256","volume":"19","author":"TJ Altree","year":"2023","unstructured":"Altree TJ, Aishah A, Loffler KA, Grunstein RR, Eckert DJ (2023) The norepinephrine reuptake inhibitor reboxetine alone reduces obstructive sleep apnea severity: a double-blind, placebo-controlled, randomized crossover trial. J Clin Sleep Med 19(1):85\u201396. https:\/\/doi.org\/10.5664\/jcsm.10256","journal-title":"J Clin Sleep Med"},{"issue":"1","key":"3724_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.chest.2021.08.080","volume":"161","author":"E Perger","year":"2022","unstructured":"Perger E, Taranto Montemurro L, Rosa D, Vicini S, Marconi M, Zanotti L, Meriggi P, Azarbarzin A, Sands SA, Wellman A, Lombardi C, Parati G (2022) Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial. Chest 161(1):237\u2013247 Epub 2021 Sep 20. PMID: 34543665; PMCID: PMC10835052","journal-title":"Chest"},{"issue":"12","key":"3724_CR14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1164\/rccm.202306-1036OC","volume":"208","author":"PK Schweitzer","year":"2023","unstructured":"Schweitzer PK, Taranto-Montemurro L, Ojile JM, Thein SG, Drake CL, Rosenberg R, Corser B, Abaluck B, Sangal RB, Maynard J (2023) The combination of Aroxybutynin and Atomoxetine in the treatment of Obstructive Sleep Apnea (MARIPOSA): a randomized controlled trial. Am J Respir Crit Care Med 208(12):1316\u20131327. https:\/\/doi.org\/10.1164\/rccm.202306-1036OC","journal-title":"Am J Respir Crit Care Med"},{"key":"3724_CR15","unstructured":"Apnimed (2025) Apnimed announces positive topline results in the first landmark phase 3 clinical trial of AD109, an investigational once-daily oral pill for obstructive sleep apnea. Apnimed [Internet] May 19 [cited 2025 Nov 1]."},{"issue":"11","key":"3724_CR16","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.5665\/sleep.2204","volume":"35","author":"DH Winslow","year":"2012","unstructured":"Winslow DH, Bowden CH, DiDonato KP, McCullough PA (2012) A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine\/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep 35(11):1529\u20131539. https:\/\/doi.org\/10.5665\/sleep.2204","journal-title":"Sleep"},{"issue":"1","key":"3724_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13256-021-03250-1","volume":"16","author":"E Grunvald","year":"2022","unstructured":"Grunvald E, DeConde J (2022) Phentermine\u2013topiramate extended release for the dual treatment of obesity and sleep-related eating disorder: a case report. J Med Case Rep 16(1):34. https:\/\/doi.org\/10.1186\/s13256-021-03250-1","journal-title":"J Med Case Rep"},{"key":"3724_CR18","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, Mignot E (2016) Effect of liraglutide 3.0\u00a0mg in individuals with obesity and moderate or severe obstructive sleep apnea: the scale sleep apnea randomized clinical trial. Int J Obes 40:1310\u20131319","journal-title":"Int J Obes"},{"key":"3724_CR19","volume":"191","author":"RS Amin","year":"2015","unstructured":"Amin RS, Simakajornboon N, Szczesniak RV (2015) Treatment of obstructive sleep apnea with glucagon like Peptide-1 receptor agonist. Am J Respir Crit Care Med 191:A4144","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 67","key":"3724_CR20","volume":"62","author":"C O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell C, O\u2019Mahony A, Traynor M, Gitau R, Ryan S (2023) Liraglutide-based weight loss versus CPAP therapy in improving sleep quality and quality of life of patients with obstructive sleep apnoea: an explorative, proof of concept study. Eur Respir J 62(Suppl 67):PA110","journal-title":"Eur Respir J"},{"key":"3724_CR21","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s11325-022-02768-y","volume":"27","author":"W Jiang","year":"2023","unstructured":"Jiang W, Li W, Cheng J et al (2023) Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. Sleep Breath 27:1687\u20131694. https:\/\/doi.org\/10.1007\/s11325-022-02768-y","journal-title":"Sleep Breath"},{"issue":"7","key":"3724_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038856","volume":"10","author":"VS Sprung","year":"2020","unstructured":"Sprung VS, Kemp GJ, Wilding JP et al (2020) Randomised, controlled multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like Peptide-1 receptor agonist), with or without continuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoea (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea\u2013hypnoea index (AHI). BMJ Open 10(7):e038856. https:\/\/doi.org\/10.1136\/bmjopen-2020-038856","journal-title":"BMJ Open"},{"key":"3724_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2147\/COPD.S350133","volume":"17","author":"AD Altintas Dogan","year":"2022","unstructured":"Altintas Dogan AD, Hilberg O, Hess S, Jensen TT, Bladbjerg EM, Juhl CB (2022) Respiratory effects of treatment with a glucagon-like Peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 17:405\u2013414","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3724_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2024.107516","volume":"141","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Bednarik J, Chakladar S, Dunn JP, Weaver T, Grunstein R, Fietze I, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Bunck MC (2024) Tirzepatide for the treatment of obstructive sleep apnea: rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial. Contemp Clin Trials 141:107516","journal-title":"Contemp Clin Trials"},{"key":"3724_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1365-2869.2012.01030.x","volume":"22","author":"I Idris","year":"2013","unstructured":"Idris I, Abdulla H, Tilbrook S, Dean R, Ali N (2013) Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea. J Sleep Res 22:70\u201375. https:\/\/doi.org\/10.1111\/j.1365-2869.2012.01030.x","journal-title":"J Sleep Res"},{"issue":"1","key":"3724_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12010011","volume":"12","author":"KDR Le","year":"2024","unstructured":"Le KDR, Le K, Foo F (2024) The impact of Glucagon-like Peptide 1 Receptor Agonists on obstructive sleep apnoea: a scoping review. Pharmacy 12(1):11. https:\/\/doi.org\/10.3390\/pharmacy12010011","journal-title":"Pharmacy"},{"issue":"5","key":"3724_CR27","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1183\/13993003.01021-2015","volume":"47","author":"JL Chapman","year":"2016","unstructured":"Chapman JL, Fiest KM, Shea SA, Peppard PE, Hanly PJ, Fleetham J et al (2016) Modafinil\/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis. Eur Respir J 47(5):1420\u20131428. https:\/\/doi.org\/10.1183\/13993003.01021-2015","journal-title":"Eur Respir J"},{"issue":"9","key":"3724_CR28","first-page":"1131","volume":"201","author":"A Malhotra","year":"2020","unstructured":"Malhotra A, Patil SP, Ayappa IA et al (2020) Solriamfetol for excessive sleepiness in OSA (TONES 3). Am J Respir Crit Care Med 201(9):1131\u20131141","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3724_CR29","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.chest.2020.09.281","volume":"159","author":"JL P\u00e9pin","year":"2021","unstructured":"P\u00e9pin JL, Georgiev O, Tiholov R, Attali V, Verbraecken J, Buyse B, Partinen M, Fietze I, Belev G, Dokic D, Tamisier R, L\u00e9vy P, Lecomte I, Lecomte JM, Schwartz JC, Dauvilliers Y, HAROSA I Study Group (2021) Pitolisant for Residual Excessive Daytime Sleepiness in Patients with OSA Adhering to CPAP: A Randomized Trial. Chest 159(4):1598\u20131609 Epub 2020 Oct 26. PMID: 33121980","journal-title":"Chest"},{"issue":"6","key":"3724_CR30","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1016\/j.chest.2020.06.078","volume":"158","author":"CN Schmickl","year":"2020","unstructured":"Schmickl CN, Landry SA, Orr JE, Chin K, Murase K, Verbraecken J et al (2020) Acetazolamide for OSA and central sleep apnea: a comprehensive systematic review and meta-analysis. Chest 158(6):2632\u20132645. https:\/\/doi.org\/10.1016\/j.chest.2020.06.078","journal-title":"Chest"},{"issue":"1","key":"3724_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/lungindia.lungindia_409_24","volume":"42","author":"A1 Tripathi","year":"2025","unstructured":"Tripathi A1, Prakash V1, Kumar H2, Arif M1, Tiwari A, Kumar S, Singh M, Sharma D, Srivastava S (2025) Comparing standard treatment of moderate to severe Obstructive Sleep Apnoea to add-on acetazolamide treatment: an open-label randomised controlled trial. Lung India 42(1):25\u201331. https:\/\/doi.org\/10.4103\/lungindia.lungindia_409_24","journal-title":"Lung India"},{"issue":"11","key":"3724_CR32","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1164\/rccm.202203-0539OC","volume":"206","author":"J Hedner","year":"2022","unstructured":"Hedner J, Zou D, Grote L et al (2022) Sulthiame for OSA: a randomized placebo-controlled trial. Am J Respir Crit Care Med 206(11):1353\u20131361","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3724_CR33","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.chest.2023.09.022","volume":"165","author":"E Hoff","year":"2024","unstructured":"Hoff E, Strassberger C, Zou D, Grote L, Stenl\u00f6f K, Hedner J (2024) Modification of endotypic traits in OSA by the Carbonic Anhydrase inhibitor Sulthiame. Chest 165(3):704\u201315. https:\/\/doi.org\/10.1016\/j.chest.2023.09.022","journal-title":"Chest"},{"issue":"10514","key":"3724_CR34","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(25)01196-1","volume":"406","author":"W Randerath","year":"2025","unstructured":"Randerath W, Grote L, Stenl\u00f6f K, Fietze I, Chevts J, Buntinx E, Albares J, Kuhn K, Hansen C, V\u00f6lp A, Hedner J (2025) Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet 406(10514):1983\u20131992. https:\/\/doi.org\/10.1016\/S0140-6736(25)01196-1","journal-title":"Lancet"},{"issue":"5","key":"3724_CR35","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1513\/AnnalsATS.201408-399OC","volume":"12","author":"ET Smales","year":"2015","unstructured":"Smales ET, Edwards BA, Deyoung PN, McSharry DG, Wellman A, Velasquez A, Owens R, Orr JE, Malhotra A (2015) Trazodone effects on obstructive sleep apnea and Non-REM arousal threshold. Ann Am Thorac Soc 12(5):758\u2013764. https:\/\/doi.org\/10.1513\/AnnalsATS.201408-399OC","journal-title":"Ann Am Thorac Soc"},{"issue":"9","key":"3724_CR36","first-page":"1310","volume":"31","author":"CJ Lettieri","year":"2008","unstructured":"Lettieri CJ, Quast TN, Eliasson AH, Andrada T (2008) Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo-controlled trial. Sleep 31(9):1310\u20131316","journal-title":"Sleep"},{"key":"3724_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101492","volume":"58","author":"SG Carter","year":"2021","unstructured":"Carter SG, Eckert DJ (2021) Effects of hypnotics on obstructive sleep apnea endotypes and severity: novel insights into pathophysiology and treatment. Sleep Med Rev 58:101492. https:\/\/doi.org\/10.1016\/j.smrv.2021.101492","journal-title":"Sleep Med Rev"},{"issue":"8","key":"3724_CR38","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/jhh.2009.96","volume":"24","author":"K Gaddam","year":"2010","unstructured":"Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA (2010) Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 24(8):532\u2013537. https:\/\/doi.org\/10.1038\/jhh.2009.96","journal-title":"J Hum Hypertens"},{"issue":"6","key":"3724_CR39","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1007\/s11325-024-03113-1","volume":"28","author":"AR Schwartz","year":"2024","unstructured":"Schwartz AR, Herpel L, Bogan R, Corser B, Pho H, Taranto-Montemurro L (2024) Atomoxetine and Spironolactone combine to reduce obstructive sleep apnea severity and blood pressure in hypertensive patients. Sleep Breath 28(6):2571\u20132580. https:\/\/doi.org\/10.1007\/s11325-024-03113-1","journal-title":"Sleep Breath"},{"issue":"1","key":"3724_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsx184","volume":"41","author":"DW Carley","year":"2018","unstructured":"Carley DW, Prasad B, Reid KJ, Malkani R, Attarian H, Abbott SM, Vern B, Xie H, Yuan C, Zee PC (2018) Pharmacotherapy of apnea by cannabimimetic enhancement, the PACE clinical trial: effects of dronabinol in obstructive sleep apnea. Sleep 41(1):zsx184. https:\/\/doi.org\/10.1093\/sleep\/zsx184","journal-title":"Sleep"},{"issue":"4","key":"3724_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsae276","volume":"48","author":"J Walsh","year":"2025","unstructured":"Walsh J, Rankin T, Mehra S, Naughton MT, Roebuck T, McDermott E, Pattichis A, Smith R, Walsh R, Bleackley M, Maddison K, O\u2019Brien TJ (2025) A randomized dose finding study of combination dronabinol and acetazolamide for the treatment of obstructive sleep apnea. Sleep 48(4):zsae276. https:\/\/doi.org\/10.1093\/sleep\/zsae276","journal-title":"Sleep"},{"issue":"5","key":"3724_CR42","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1152\/japplphysiol.01074.2020","volume":"130","author":"A Aishah","year":"2021","unstructured":"Aishah A, Lim R, Sands SA, Taranto-Montemurro L, Wellman A, Carberry JC, Eckert DJ (2021) Different antimuscarinics when combined with atomoxetine have differential effects on Obstructive Sleep Apnea severity. J Appl Physiol 130(5):1373\u20131382. https:\/\/doi.org\/10.1152\/japplphysiol.01074.2020","journal-title":"J Appl Physiol"},{"issue":"9","key":"3724_CR43","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1513\/AnnalsATS.202409-923OC","volume":"21","author":"AE Henney","year":"2024","unstructured":"Henney AE, Riley DR, Anson M, Heague M, Hernandez G, Alam U, Craig S, Cuthbertson DJ (2024) Comparative efficacy of tirzepatide, liraglutide, and semaglutide in reduction of risk of major adverse cardiovascular events in patients with obstructive sleep apnoea and type 2 diabetes: real-world evidence. Ann Am Thorac Soc 21(9):1234\u20131242. https:\/\/doi.org\/10.1513\/AnnalsATS.202409-923OC","journal-title":"Ann Am Thorac Soc"},{"key":"3724_CR44","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s11606-025-09950-4","volume":"41","author":"L Zhou","year":"2026","unstructured":"Zhou L, Wei A, Pan C et al (2026) Effects of Glucagon-Like Peptide-1 Receptor Agonists After Treatment Withdrawal: A Systematic Review and Meta-Analysis. J GEN INTERN MED 41:807\u2013818. https:\/\/doi.org\/10.1007\/s11606-025-09950-4","journal-title":"J GEN INTERN MED"},{"key":"3724_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085304","volume":"392","author":"S West","year":"2026","unstructured":"West S, Scragg J, Aveyard P, Oke JL, Willis L, Haffner SJP et al (2026) Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ 392:e085304. https:\/\/doi.org\/10.1136\/bmj-2025-085304","journal-title":"BMJ"},{"issue":"2","key":"3724_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1164\/rccm.201802-0240OC","volume":"199","author":"CD Turnbull","year":"2019","unstructured":"Turnbull CD, Sen D, Kohler M, Petousi N, Stradling JR (2019) Effect of supplemental oxygen on blood pressure in obstructive sleep apnea (SOX). A randomized continuous positive airway pressure withdrawal trial. Am J Respir Crit Care Med 199(2):211\u2013219. https:\/\/doi.org\/10.1164\/rccm.201802-0240OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"24","key":"3724_CR47","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1056\/NEJMoa1306766","volume":"370","author":"DJ Gottlieb","year":"2014","unstructured":"Gottlieb DJ, Punjabi NM, Mehra R, Patel SR, Quan SF, Babineau DC, Tracy RP, Rueschman M, Blumenthal RS, Lewis EF, Bhatt DL, Redline S (2014) CPAP versus oxygen in obstructive sleep apnea. N Engl J Med 370(24):2276\u20132285. https:\/\/doi.org\/10.1056\/NEJMoa1306766","journal-title":"N Engl J Med"},{"issue":"3","key":"3724_CR48","doi-asserted-by":"publisher","first-page":"1800674","DOI":"10.1183\/13993003.00674-2018","volume":"52","author":"SA Sands","year":"2018","unstructured":"Sands SA, Edwards BA, Terrill PI, Butler JP, Owens RL, Taranto-Montemurro L, Azarbarzin A, Marques M, Hess LB, Smales ET, de Melo CM, White DP, Malhotra A, Wellman A (2018) Identifying obstructive sleep apnoea patients responsive to supplemental oxygen therapy. Eur Respir J 52(3):1800674 PMID: 30139771; PMCID: PMC6232193","journal-title":"Eur Respir J"},{"issue":"6","key":"3724_CR49","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1164\/rccm.202308-1497OC","volume":"209","author":"L Messineo","year":"2024","unstructured":"Messineo L, Wilcox S, Catcheside PG, Al-Ani M, Butler JE, Eckert DJ (2024) Effects of hypnotics on arousal threshold and Obstructive Sleep Apnea severity: a systematic review and meta-analysis. Am J Respir Crit Care Med 209(6):510\u201321. https:\/\/doi.org\/10.1164\/rccm.202308-1497OC","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Sleep and Breathing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-026-03724-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11325-026-03724-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11325-026-03724-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:59:00Z","timestamp":1787144340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11325-026-03724-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3724"],"URL":"https:\/\/doi.org\/10.1007\/s11325-026-03724-w","relation":{},"ISSN":["1520-9512","1522-1709"],"issn-type":[{"value":"1520-9512","type":"print"},{"value":"1522-1709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Funding: This study received no funding.","order":1,"name":"Ethics","label":"Compliance with ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors, Dr. John R Kimoff, Dr. Lancelot Pinto and Dr. Shashank Shastry declare that they have no conflicts of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"231"}}